Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03345082 · ClinicalTrials.gov registry record · Phase 2
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Phase 2 study, sponsored by Opthea Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 366
- Enrollment target
NCT03345082 is a Phase 2 study that has completed, run by Opthea Limited. The registered enrollment target is 366 participants.
The verdict
NCT03345082, a Phase 2 study, has completed, sponsored by Opthea Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 366 participants
- Enrollment target
Study Summary
A multicentre, randomised, parallel group, sham-controlled, double-masked, dose-ranging study, investigating two doses of OPT-302 in combination with ranibizumab compared with ranibizumab with sham, over six consecutive monthly dosing cycles in participants with neovascular (wet) AMD.
Interventions
- BIOLOGICAL ranibizumab
- BIOLOGICAL OPT-302
- OTHER sham intravitreal injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2017-11-06 |
| Est. Completion | 2019-05-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03345082
The ClinicalTrials.gov registry entry for NCT03345082 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Opthea Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ranibizumab is the first listed.
NCT03345082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03345082 about?
NCT03345082 is a clinical study titled "A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD". A multicentre, randomised, parallel group, sham-controlled, double-masked, dose-ranging study, investigating two doses of OPT-302 in combination with ranibizumab compared with ranibizumab with sham, over six consecutive monthly dosing cycles in participants with neovascular (wet) AMD.
What is the current status of trial NCT03345082?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 366 participants. The study started on 2017-11-06. Estimated completion is 2019-05-14.
What interventions are being tested in trial NCT03345082?
The interventions under investigation include: ranibizumab (BIOLOGICAL), OPT-302 (BIOLOGICAL), sham intravitreal injection (OTHER).
Who is sponsoring clinical trial NCT03345082?
This trial is sponsored by Opthea Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.